Association between baseline hs-CRP levels and the endpoints, adjusted for clinical characteristics, NT-proBNP and hs-TnT
| Death or HF (n=69) | MACE (n=228) | |||
| HR (95% CI) | P value | HR (95% CI) | P value | |
| Baseline hs-CRP, mg/L (unadjusted) | 1.36 (1.19 to 1.55) | <0.001 | 1.08 (1.00 to 1.16) | 0.038 |
| Adjusted for: | ||||
| Baseline NT-proBNP | 1.19 (1.04 to 1.37) | 0.014 | 1.00 (0.92 to 1.07) | 0.910 |
| Baseline hs-TnT | 1.35 (1.18 to 1.56) | <0.001 | 1.08 (1.00 to 1.16) | 0.059 |
| Baseline characteristics* | 1.21 (1.05 to 1.40) | 0.008 | 1.02 (0.95 to 1.10) | 0.587 |
| Baseline characteristics* and NT-proBNP | 1.18 (1.03 to 1.35) | 0.016 | 1.00 (0.93 to 1.08) | 0.989 |
| Baseline characteristics*and hs-TnT | 1.18 (1.03 to 1.35) | 0.018 | 1.02 (0.95 to 1.10) | 0.594 |
| Baseline characteristics* NT-proBNP and hs-TnT | 1.17 (1.02 to 1.34) | 0.023 | 1.00 (0.93 to 1.08) | 0.987 |
HRs are expressed per twofold higher biomarker level.
*Age, sex, congenital diagnosis (aortic stenosis, aortic coarctation, transposition of the great arteries operated by arterial switch procedure vs the other diagnoses), NYHA (NYHA I vs NYHA II/III), cardiac medication use (no vs yes), systemic ventricular function (0–3).
HF, heart failure; hs-CRP, high-sensitivity C reactive protein; hs-TnT, high-sensitivity troponin T; MACE, major adverse cardiac event; NT-proBNP, N-terminal pro B type natriuretic peptide.